Shanghai Medical College

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

Retrieved on: 
Friday, April 21, 2023

SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).

Key Points: 
  • SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).
  • Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall corporate strategy planning and implementation.
  • Dr. Kong holds a doctor's degree from Shanghai Medical College of Fudan University and a master's degree of Science in Molecular Immunology from University of Nebraska Medical Center.
  • Before joining ImmVira, he served as Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, Vice President of Clinical Oncology at Hengrui Therapeutics, Senior Global Medical Leader of Global Medical Affairs at Novartis Oncology, Senior Medical Director at Celegene and Medical Director of US Medical Affairs at Bayer HealthCare Pharmaceuticals.

Asieris Appoints Dr. Linda Wu as Chief Development Officer

Retrieved on: 
Tuesday, January 17, 2023

SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023.

Key Points: 
  • SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023.
  • Dr. Wu will be based in the United States and report to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris.
  • Dr. Wu joins Asieris from Janssen Pharmaceuticals, a Johnson & Johnson company, where she most recently served as a Group Medical Director of Oncology, US Medical Affairs.
  • "I am thrilled and deeply honored to be appointed as Chief Development Officer at Asieris.

GenomiCare Biotechnology Appoints Dr. Shusen Liu as Chief Medical Officer

Retrieved on: 
Thursday, January 20, 2022

HAVERFORD, Pa., Jan. 20, 2022 (GLOBE NEWSWIRE) -- GenomiCare Biotechnology, a leader in precision medicine of Chinese cancer patients and the application of RWD to pharmaceutical research and development, today announced the recent appointment of Shusen Liu, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • HAVERFORD, Pa., Jan. 20, 2022 (GLOBE NEWSWIRE) -- GenomiCare Biotechnology, a leader in precision medicine of Chinese cancer patients and the application of RWD to pharmaceutical research and development, today announced the recent appointment of Shusen Liu, M.D., Ph.D., as Chief Medical Officer.
  • "We are pleased to welcome Dr. Shusen Liu to GenomiCare Biotechnology as Chief Medical Officer, said Dr. Qiang Xu, GenomiCares President and CEO.
  • On his appointment Dr. Liu said, As Chief Medical Officer of GenomiCare Biotechnology, I am looking forward to taking advantage of my experience in the RWD research and making contributions to the RWD strategy and commercial expansion.
  • His He has also served as Vice President, Chief Medical Evidence Officer, at Digital China Health (DCH).

The International Society of Gastrointestinal Oncology Welcomes Dr. Weijing Sun as President

Retrieved on: 
Tuesday, October 26, 2021

CRANBURY, N.J., Oct. 26, 2021 /PRNewswire/ -- The International Society of Gastrointestinal Oncology (ISGIO) , a nonprofit global educational organization committed to gastrointestinal (GI) oncology, recently named Dr. Weijing Sun its new president.

Key Points: 
  • CRANBURY, N.J., Oct. 26, 2021 /PRNewswire/ -- The International Society of Gastrointestinal Oncology (ISGIO) , a nonprofit global educational organization committed to gastrointestinal (GI) oncology, recently named Dr. Weijing Sun its new president.
  • The International Society of Gastrointestinal Oncology Welcomes Dr. Weijing Sun as President
    "I am honored to welcome Dr. Sun as the new president of the ISGIO," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of ISGIO.
  • "I have no doubt that as an established and highly respected authority in the gastrointestinal oncology space, he will be an outstanding leader."
  • For more information on the International Society for Gastrointestinal Oncology (ISGIO) and Dr. Weijing Sun, click here .